Q32 Bio to Present Bempikibart Data at EADV 2026
Waltham, Massachusetts, U.S., September 21, 2026 Q32 Bio Inc., a clinical-stage biotechnology company developing therapies for autoimmune and inflammatory...
alopecia areata
Advertisement
Co-Diagnostics Highlights Ebola Testing and Outbreak Innovation
Salt Lake City, Utah, U.S., September 21, 2026 Co-Diagnostics, Inc. is strengthening its role in global infectious-disease diagnostics and...
HCW Biologics Strengthens HCW9302 Patent for Alopecia Areata
MIRAMAR, Fla., Sept. 2, 2026 HCW Biologics Inc. (NASDAQ: HCWB), a clinical-stage biopharmaceutical company developing fusion immunotherapeutics for autoimmune...
argenx Completes Forte Biosciences Acquisition for FB102
Amsterdam, the Netherlands – August 27, 2026 argenx announced the successful completion of its acquisition of Forte Biosciences, Inc.,...
HCW Biologics Advances HCW9302 in Alopecia Areata
MIRAMAR, Fla., August 14, 2026 HCW Biologics Inc. (NASDAQ: HCWB) reported second-quarter 2026 business and clinical development updates, highlighting...
Advertisements
argenx SE Expands Immunology Pipeline with Forte Biosciences Deal
Amsterdam, the Netherlands and Dallas, Texas – July 27, 2026 argenx has entered into a definitive agreement to acquire...
Q32 Bio Reports Positive Phase 2a Alopecia Trial Results
WALTHAM, Mass., July 13, 2026 Q32 Bio has announced positive 36-week topline results from Part B of the Phase...
Roche Enspryng Gains FDA Priority Review for TED Treatment
BASEL, Switzerland, June 30, 2026 Roche has announced that the U.S. Food and Drug Administration (FDA) has granted Priority...
AbbVie RINVOQ® Moves Closer to EU Approval for Alopecia Areata
NORTH CHICAGO, Ill., June 29, 2026 AbbVie has announced that the European Medicines Agency’s Committee for Medicinal Products for...
Astellas and Pfizer Gain FDA Priority Review for PADCEV Combo
TOKYO, Japan and NEW YORK, U.S., April 20, 2026 Astellas Pharma Inc. and Pfizer Inc. have announced that the...
Advertisement
